AGP Picks
View all

Middle East FinTech today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East FinTech today.

Press releases published on May 22, 2026

EMGA obtém financiamento de US$ 15 milhões para o Asia Alliance Bank junto ao OeEB
EMGA จัดหาเงินทุนมูลค่า 15 ล้านดอลลาร์สหรัฐให้กับ Asia Alliance Bank จาก OeEB
EMGA 助力 Asia Alliance Bank 从 OeEB 获得 1,500 万美元融资
EMGA 牽線 OeEB,為 Asia Alliance Bank 安排 1,500 萬美元的融資
Atlantic American Corporation Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Alerus Financial Corporation Declares Cash Dividend on Common Shares
SHARC Energy Oversubscribes Closing of Third Tranche of Debenture Exercising 25% Overallotment
Apogee Acquisition Corp Announces the Separate Trading of Its Class A Ordinary Shares, Warrants and Rights, Commencing on May 28, 2026
Terra Innovatum Provides Update on Form 10-K and First Quarter 2026 Reporting Timeline
SCYNEXIS Announces One-for-Eight Reverse Stock Split
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
NANOBIOTIX annonce l’exercice integral de l’option de surallocation, portant le produit de l'offre a 100 millions de dollars
ACP Holdings Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about May 28, 2026
Japan Smaller Capitalization Fund, Inc. Announces Commencement of Tender Offer and Re-Leveling of Level Distribution Plan
Orange County Bancorp, Inc. Declares Cash Dividend
Mission Produce and Calavo Growers Merger Obtains Mexican Antitrust Approval
Rural America Has Been Left Behind for Decades. Ex-Wall Street Expert Says That Era Is Finally Ending
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Middle East FinTech today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.